[
    [
        {
            "time": "",
            "original_text": "凯莱英(002821.SZ)：回购注销6.24万股限制性股票",
            "features": {
                "keywords": [
                    "凯莱英",
                    "回购注销",
                    "限制性股票"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "凯莱英(002821.SZ)：回购注销6.24万股限制性股票",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业日报：医药指数创近五年来新高",
            "features": {
                "keywords": [
                    "医药生物",
                    "行业日报",
                    "医药指数",
                    "新高"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业日报：医药指数创近五年来新高",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "四个月内连下三家上市公司，400亿定增资金注入！顶级战投为何偏爱国内医药市场？",
            "features": {
                "keywords": [
                    "定增资金",
                    "医药市场",
                    "投资"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "四个月内连下三家上市公司，400亿定增资金注入！顶级战投为何偏爱国内医药市场？",
                "Correlation": 5,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业日报：医药高位震荡格局延续",
            "features": {
                "keywords": [
                    "医药生物",
                    "行业日报",
                    "高位震荡"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药生物行业日报：医药高位震荡格局延续",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【华西医药崔文亮团队】《医药生物行业点评报告：两会医药议题解读：疫苗、创新药、IVD和医疗设备等领域继续成为关注焦点》",
            "features": {
                "keywords": [
                    "医药生物",
                    "两会",
                    "疫苗",
                    "创新药",
                    "IVD",
                    "医疗设备"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【华西医药崔文亮团队】《医药生物行业点评报告：两会医药议题解读：疫苗、创新药、IVD和医疗设备等领域继续成为关注焦点》",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]